Status:
UNKNOWN
Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure
Lead Sponsor:
Third Affiliated Hospital, Sun Yat-Sen University
Conditions:
Liver Failure
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
HBV-related liver failure (HBV-LF), a dramatic clinical syndrome, is characterized with massive necrosis of liver cells. Liver transplantation might be the most effective therapy for HBV-LF. However, ...
Eligibility Criteria
Inclusion
- Aged 18-65 years
- Liver failure
- Negative pregnancy test (female patients in fertile age)
- Written consent
- HBsAg positive
- TB≥171 μmol/L or ascend ≥17.1 μmol/L/per day,
- INR≥1.5 or 20%\<PTA≤40%
- 17≤MELD score≤30
Exclusion
- Hepatocellular carcinoma or other malignancies
- Severe problems in other vital organs(e.g.the heart,renal or lungs)
- Pregnant or lactating women
- Severe bacteria infection
- Anticipated with difficulty of follow-up observation
- Liver failure caused by other reasons, such as autoimmune diseases, alcohol, drug and so on
- Other candidates who are judged to be not applicable to this study by doctors
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2019
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT01844063
Start Date
July 1 2013
End Date
January 1 2019
Last Update
July 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qi Zhang
Guangzhou, Guangdong, China, 510630